Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.23 on Tuesday. The company has a market capitalization of $13.56 million, a price-to-earnings ratio of -0.08 and a beta of 1.07. The company’s 50 day simple moving average is $0.27 and its 200-day simple moving average is $0.43. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.60.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.